Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agree but it's slim chance just like SUNE Q that's all. Good Luck too all
Agreed this is a great Loading Zone:)
$BRNW
Agreed day trade only I bought back in yesterday as well. Monday could see a run for sure.
Better get what you can before its on the OTC no more Nasdaq soon! I'm out
In for some $$$ Looking for recovery!!
$NUGT
There was a mad exitus at the EOD!!!
Oh what does that say?
$TTCM
It's amazing that the truth is distorted! In the end the stock is headed down down down to the ground. On IHUB we have freedom of speech except for certain things that go against the TOS. As we all know everyone has an opinion which we are entitled to. They are broke,late, diluting and have a yield sign in their front yard. With all that said who's going to put their money into something that is so far gone?
:( 1~Eye~Jack!! Statements are to protect the investor NOT hurt them!!!
Seek out the truth and you will find out what the truth is!!!
$TTCM
Agreed but overseas should be concerned about what happened today. I just hope fear sets in and we fly tomorrow! Lol
$DUST
Oil down caused the drop it should pop again.
I think overnight will stay red before opening bell~fingers crossed! I would love to see dusty 16-17 tomorrow. :)
$DUST
Holding overnight looking for a 16$ gap in the morning!!!
$DUST
Oil is down and gold will continue to get trashed overnight. I see swings .055-.065 for a while
O Boy!!! Let the fun begin!!! Lol I just said get out while you can and looky what we have here!!!
$TTCM :(
Better take profits before its to late!
$TTCM
Half baked turd setting @ .01 right now so sad! :(
$TTCM
Shaking the NaY NaY today!!! Lol Issued Shares = DILUTION = Lower Lows!!! :( Get Out While You Can!!! :(
$TTCM
Good Morning! I think your right we will see some movement in the PPS but declining! :( No News has lit the fuse to newer Lows! :(
$TTCM
The way the board feels Gold should drop like a rock soon
But we will still have 10% swings no matter the pps price right?
Monday looks to be interesting
Looking forward to a fabulous Friday!!! :)
$RGBPP
I think we hit .25-.30 in a few days just my feeling.
$RGBPP
HemaXellerate~Moving on from Phase l and updates coming!!! :)
Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS
HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning.
Fat stem cell based product to treat bone marrow that has been damaged
Bone marrow damage occurs from radiation, chemo, or chronic conditions
HemaXellerate uses patient’s own fat as source of endothelial cells to heal damaged bone marrow
?United States Food and Drug Administration Investigational New Drug Application cleared (IND #15376)
I think there are a lot of eyes on us lately! In time all the work will pay off!
$RGBPP
Yes I believe both stocks will benefit from future progress! :)
$RGBPP
News~HemaXellerate Works!!! :) An increase in white blood cells in the patients at only 1 month! :)
7:00 AM ET 5/3/16 | PR Newswire
Regen BioPharma, Inc. (OTCBB: RGBP), (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today that the Pan Am Cancer Treatment Center in Tijuana, Mexico, which has a non-exclusive license to test HemaXellerate in a first-in-human proof of concept study, presented interim clinical data on their first 5 patients. Beginning in March 2016, 5 patients with chemotherapy-induced bone marrow suppression were treated with HemaXellerate and initial 1 month follow up data were provided. The primary endpoint of the study is safety and the secondary endpoint is effectiveness.
Regarding safety, none of the 5 patients had any adverse events. In other words, all of the patients tolerated HemaXellerate with no side-effects. Effectiveness was measured by taking blood tests of the patients 1 month post-HemaXellerate treatment and measuring the levels of blood cells, particularly immune cells, circulating in their blood. At 1 month post-HemaXellerate treatment, 2 patients (40%) had a dramatic increase in their circulating white blood cells to levels even above the normal range and 2 other patients had their white blood cells return to the normal range.
"These data are interesting. While there is no control group which would help us determine if the patients in which their white blood cell counts returned to the normal range is a consequence of HemaXellerate treatment, the apparent profound increase in white blood cell counts in two other patients suggests that HemaXellerate may have some effectiveness," said Harry Lander, Ph.D., MBA, President and CSO. "However, it is clear that HemaXellerate was quite safe in these patients which is our primary concern."
"We were delighted that our licensees initiated this trial. It is gratifying to see that HemaXellerate may have some benefit to these patients," said Dr. David Koos, CEO. "Because this is an investigator-initiated trial we don't have control over the experimental design, but we are delighted that it is progressing. Let's remember, this is a first-in-human trial and so understanding the safety profile of HemaXellerate is critical."
HemaXellerate is comprised of cells extracted from the patient's own fat tissue and processed using a proprietary method so as to induce a biological response in the patient that heals damaged bone marrow and restores the body's ability to generate healthy blood cells. The FDA recently cleared Regen to perform Phase I clinical trials in the U.S. using HemaXellerate in aplastic anemia patients.
About Regen BioPharma, Inc.
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP), (OTC PINK: RGBP) and (OTC PINK: RGBPP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.
*HemaXellerate*~ Studies taking ground!!!
Regen BioPharma, Inc. (OTCBB: RGBP) and (PINK: RGBP) has entered into a non-exclusive license agreement with Pan Am Cancer Treatment Center in Tijuana, Mexico to test HemaXellerate in a first-in-human proof of concept study. Up to 10 patients with chemotherapy-induced aplastic anemia will be treated with HemaXellerate, and outcomes will be measured at one, three and six months. This study was initiated by Dr. Julio Selva Pallares, Professor of Clinical Hematology at the Autonomous University of Baja California and Director of its hematology transfusion unit.
"We were delighted that Dr. Pallares initiated this trial and that Regen could support him. We hope that HemaXellerate will benefit these patients," said Dr. David Koos, CEO of Regen BioPharma. "As an investigator-initiated trial, the license does not have a financial component. The first-in-human study, however, is very valuable to our research."
HemaXellerate is comprised of cells extracted from the patient's own fat tissue and processed using a proprietary method to induce a biological response in the patient that heals damaged bone marrow and restores the body's ability to generate healthy blood cells. The FDA recently cleared Regen to perform phase I clinical trials in the U.S. using HemaXellerate for patients battling aplastic anemia.
"It is very exciting to have our first clinical stage product licensed for a proof of concept study so quickly. Our HemaXellerate program is advancing, and we anticipate the other autologous cell therapies for which we are seeking FDA IND clearance, dCellVax and tCellVax, to follow a similar path," said Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen.
The license granted to Pan Am Cancer Treatment Center grants only the right to test HemaXellerate in a human proof of concept study. The license granted does not permit Pan Am Cancer Treatment Center to market the therapy or provide the therapy to any party other than in connection with their study.
About Regen BioPharma, Inc.
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP), (OTC PINK: RGBP) and (OTC PINK: RGBPP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
http://www.regenbiopharma.com and http://www.regenbiopharmainc.com
Twitter: Regen BioPharma News: https://twitter.com/RegenBioPharm
Contact:
Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
David.koos@regenbiopharma.com
The Dorsee Company
Debra Dorsee
+1-(858)-229-6082
Debbie@thedorseecompany.com
Yes I remember that day too!!! It won't be long before we are there again!
$RGBPP
Yes very thin and there was a lot of nice Buy's today!
$RGBPP
Loaded Down~Ready for Dollars!!!
$RGBPP
Amen!!! When there's blood in the water something great is coming! The new SA post is a time consuming post and shows the desperation. I hope we raise the pps up today in spite of the article written! Lol
$SUNEQ
$RGBP~$RGBPP-***News***
Regen BioPharma, Inc. Discusses Recent Developments in Aplastic Anemia Therapy and Future Potential Expansion of HemaXellerate
http://www.prnewswire.com/news-releases/regen-biopharma-inc-discusses-recent-developments-in-aplastic-anemia-therapy-and-future-potential-expansion-of-hemaxellerate-578950301.html
$RGBP~$RGBPP-***News***
Regen BioPharma, Inc. Discusses Recent Developments in Aplastic Anemia Therapy and Future Potential Expansion of HemaXellerate
http://www.prnewswire.com/news-releases/regen-biopharma-inc-discusses-recent-developments-in-aplastic-anemia-therapy-and-future-potential-expansion-of-hemaxellerate-578950301.html
Regen BioPharma, Inc. Discusses Recent Developments in Aplastic Anemia Therapy and Future Potential Expansion of HemaXellerate
http://www.prnewswire.com/news-releases/regen-biopharma-inc-discusses-recent-developments-in-aplastic-anemia-therapy-and-future-potential-expansion-of-hemaxellerate-578950301.html
Koo's rising lets go!!! Let's get some juicy news!!!
$RGBP
Agreed~Looking for the run to start soon!
$RGBPP
TOur DE PiG!!! Lol I don't think so! What good would that do for a looser like we have here!!! Will we loose another 5 or 10% today? :(
$TTCM
I hate to break the News but there is Only One Reason The War Mister is here!!! We are on the southbound train to nowhere!!! Lol Say Oink Oink to this Slaughtered Pig that TTCM Is!!!
When did dilution hits still no fins to report the only thing left of this Pig will be a Pile of Pigs in the Blanket!!!
$TTCM
Nice jump today!
$RGBPP
Agreed and I've said this so many times it makes my Feather's Itch!!! .02 are history and this Pig is off to the Slughter!!! :( .000 Coming to a account near _____!!!!
$TTCM